Continued losses due to front-loaded investment in drug discovery platforms and proprietary development
First written in FY2024. 4 of 6 entries say "Worsened", first in FY2025-H1. Latest entry: 2026-08-14.
PRISM BioLab moved to the "Worse" side of this theme in 2025, 4 years after the typical company in this theme (2021).
The whole theme swung hardest in 2021: 5 of 10 companies on the "Worse" side.
5 other companies' latest entry also says "Worsened".
- FY2025Losses narrowed, but remained ongoingAnnual report
「As a result, the operating loss was ¥774.453 million (an operating loss of ¥782.392 million in the previous fiscal year), the ordinary loss was ¥748.302 million (an ordinary loss of ¥831.518 million in the previous fiscal year), and the net loss was ¥833.700 million (a net loss of ¥1,049.514 million in the previous fiscal year).」
The operating loss, ordinary loss and net loss all continued, but the magnitude of the losses narrowed from the previous fiscal year. - FY2025-H1WorsenedAnnual report
「As a result, the operating loss was ¥460.605 million (an operating loss of ¥334.331 million in the previous interim accounting period), the ordinary loss was ¥432.376 million (an ordinary loss of ¥322.855 million in the previous interim accounting period), and the interim net loss was ¥474.387 million (an interim net loss of ¥336.052 million in the previous interim accounting period).」
Losses associated with upfront investment in drug discovery infrastructure and in-house development continued, and the operating loss, ordinary loss and interim net loss all increased from the same period of the previous year. - FY2024First statedAnnual report
「The ninth, 10th, 12th and 13th fiscal years resulted in ordinary losses and net losses due to upfront research and development investment to establish the foundation for the drug discovery business.」
For the fiscal year, revenue was ¥305.620 million, ordinary loss was ¥831.518 million and net loss was ¥1,049.514 million.